10-Q: NexGel Inc. Reports Increased Revenue Driven by Branded Consumer Products in Q2 2024

NexGel, Inc. saw a 23.4% increase in revenue in the second quarter of 2024, primarily driven by growth in its branded consumer products segment.

Summary

• NexGel, Inc. reported a revenue of $1.44 million for the three months ended June 30, 2024, a 23.4% increase compared to $1.167 million for the same period in 2023.
• The revenue growth was mainly due to the expansion of the branded consumer products line, including the acquisition of Silly George, which contributed $380 thousand in revenue from May 15 to June 30, 2024.
• Gross profit for the quarter was $410 thousand, a significant increase from $175 thousand in the same period last year, with gross profit margin improving to 28.5% from 15.0%.
• Operating expenses increased to $1.464 million, up from $937 thousand, primarily due to higher selling, general, and administrative costs.
• The company reported a net loss of $979 thousand for the quarter, compared to a net loss of $642 thousand in the same period of 2023.
• For the six months ended June 30, 2024, revenue was $2.706 million, a 51.5% increase from $1.786 million in the same period of 2023.
• The net loss attributable to NexGel stockholders for the six months ended June 30, 2024 was $1.738 million, compared to $1.509 million for the same period in 2023.
• The company had a cash balance of $1.1 million as of June 30, 2024, and a working capital of $1.0 million.

Sentiment

Score: 5

Explanation: The document shows strong revenue growth and strategic acquisitions, but the increasing net losses and operating expenses raise concerns. The company is in a growth phase but needs to improve profitability.

Positives

• The company experienced significant revenue growth, particularly in its branded consumer products segment.
• Gross profit margins improved substantially, indicating better profitability on sales.
• The recent acquisitions of Silly George and Kenkoderm are contributing to revenue growth.
• The company successfully raised capital through registered direct offerings.
• The company is expanding its product portfolio and exploring new sales channels.

Negatives

• The company continues to incur net losses, with a net loss of $979 thousand for the quarter and $1.738 million for the six months ended June 30, 2024.
• Operating expenses, particularly selling, general, and administrative costs, have increased significantly.
• The company's cash balance decreased to $1.1 million as of June 30, 2024.
• The company has a working capital of $1.0 million as of June 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on managing and growing current products and achieving profitable operations.
• The company may need to raise additional capital through debt or equity offerings.
• The company is exposed to risks related to mergers and acquisitions, including implementation costs and failure to achieve expected gains.
• The company is subject to risks related to adverse economic conditions, intense competition, and loss of key customers or suppliers.
• The company is subject to risks related to technological obsolescence and technical problems with research and products.

Future Outlook

The company plans to continue building and developing its catalog of consumer products, explore new sales channels, develop proprietary medical devices, and evaluate strategic initiatives, including potential acquisitions and additional capital raises.

Management Comments

• Management is exploring new product channel sales in adjacent industries, such as cosmetics, athletic products, and proprietary medical devices.
• The Company has increased focus on sales and developing a sales pipeline for potential customers.
• We have sufficient capital to maintain as a going concern due to the recent capital raises.
• We intend to maintain and attempt to grow our existing contract manufacturing business.
• We also plan to continue building and developing our catalog of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products.

Industry Context

The company's focus on branded consumer products aligns with the broader trend of direct-to-consumer sales and the growing demand for health and beauty products. The acquisitions of Kenkoderm and Silly George are strategic moves to expand the company's presence in these markets.

Comparison to Industry Standards

• NexGel's revenue growth of 23.4% in Q2 2024 is strong compared to the average growth rate in the medical device and consumer health sectors, which typically see single-digit growth.
• The gross profit margin of 28.5% is competitive, but the company needs to improve its operating expenses to achieve profitability.
• Compared to companies like Johnson & Johnson or Procter & Gamble, NexGel is still in an early growth phase, with a focus on expanding its product portfolio and market reach.
• The company's reliance on a few key customers is a risk, similar to other small to medium sized contract manufacturers, and diversification is needed.
• The company's recent acquisitions are similar to strategies used by larger companies to expand into new markets and product categories.

Related Party Transactions

• Dr. Jerome Zeldis, a member of the Company board of directors, has an outstanding balance due of $25,000 for services as of June 30, 2024.

Stakeholder Impact

• Shareholders may be concerned about the continued net losses, but encouraged by the revenue growth and strategic acquisitions.
• Employees may benefit from the company's growth and expansion.
• Customers may benefit from the company's expanded product portfolio.
• Suppliers may see increased business opportunities with the company's growth.

Next Steps

• The company plans to continue building and developing its catalog of consumer products.
• The company will explore new sales channels.
• The company will develop proprietary medical devices.
• The company will evaluate strategic initiatives, including potential acquisitions.
• The company will continue to evaluate additional capital raises through debt or equity.

Key Dates

Keywords

hydrogels, contract manufacturing, branded consumer products, medical devices, skincare, cosmetics, joint venture, acquisition, revenue, net loss, operating expenses, capital raise